Cited by 497Venous Thromboembolism Diagnosis and ManagementSystemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy

Schulman, Sam, Svenungsson, Elisabet, Granqvist, Staffan·1998·The American Journal of Medicine

DOI 10.1016/s0002-9343(98)00060-6

Open this paper in CoChat — free account

Abstract

Purpose To compare the risk of recurrent venous thromboembolism in patients with and without antiphospholipid antibodies.Patients and methods Anticardiolipin antibodies were tested 6 months after a first or second episode of venous thromboembolism. Of the patients with a first episode of venous thromboembolism only the 412 who received 6 months of anticoagulation were studied. Two hundred and eleven patients with a second episode received oral anticoagulation for 6 months or indefinitely. The therapy was targeted at an international normalized ratio (INR) of 2.0 to 2.85. All patients were followed up for 4 years after enrollment.Results Among the 412 patients with a first episode of venous thromboembolism the risk of recurrence was 29% in patients with anticardiolipin antibodies and 14% in those without antibodies (P = 0.0013). In those with antibodies, there was an increased risk during the first 6 months after cessation of anticoagulation. The risk of recurrence increased with the titer of the antibodies. Four-year mortality rate was 15% in those with antibodies and 6% in those without (P = 0.01). Among 34 patients with a second event of venous thromboembolism and anticardiolipin antibodies, there were no recurrences during anticoagulant therapy versus 20% in those who received only 6 months of treatment (P = 0.08).Conclusions The presence of elevated titers of anticardiolipin antibodies 6 months after an episode of venous thromboembolism is a predictor for an increased risk of recurrence and of death. Patients with anticardiolipin antibodies and venous thromboembolism seem to benefit from prolonged oral anticoagulation.

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(98)00060-6

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Self-citation
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
Schulman, S., Granqvist, S., Holmström, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S. ‐., Nordlander, S., Lärfars, G., Leijd, B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702063360601 · Cited by 595
Self-citation
Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-997 · Cited by 526
Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients
Vianna, J. L., Khamashta, M. A., Ordi, J., Font, J. A., Cervera, R., López‐Soto, A., Tolosa, C., Franz, J. K., Selva-O’Callaghan, A., Ingelmo, M., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90108-2 · Cited by 466
Antiphospholipid Antibodies and venous thromboembolism
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J. (1995) · Blood · doi:10.1182/blood.v86.10.3685.bloodjournal86103685 · Cited by 365
ANTIBODIES TO CARDIOLIPIN IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION: AN ASSOCIATION WITH RECURRENT CARDIOVASCULAR EVENTS
Hamsten, A., Björkholm, M., Norberg, R., Fairé, U. D., & Holm, G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92258-0 · Cited by 356
LACTATE AS ENERGY SOURCE FOR BRAIN IN GLUCOSE-6-PHOSPHATASE DEFICIENT CHILD
Fernandes, J., Berger, R. M. F., & Smit, G. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90257-4 · Cited by 319
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.
Derksen, R. H. W. M., de Groot, P. G., Kater, L., & Nieuwenhuis, H. K. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.9.689 · Cited by 240

Show all 24 references

Research works printed but not linked: 2

Harris EN, Chan JKH, Asherson RA, et al. IgG anticardiolipin antibody (ACAG): possible predictor for thrombosis, thrombocytopenia and recurrent abortion. Arthritis Rheum 1985;28:S38. Abstract.
1993, Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE), Haematologica, 78, 313

Sorted by citations

Items 101–200 of 493

Clinical and epidemiological aspects in the antiphospholipid syndrome
Cervera, R., & Asherson, R. A. (2003) · Immunobiology · doi:10.1078/0171-2985-00213 · Cited by 66
The treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 66
Antiphospholipid syndrome: frequency, main causes and risk factors of mortality
Espinosa, G., & Cervera, R. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.47 · Cited by 65
Antiphospholipid antibodies and thrombosis: strength of association
Galli, M., & Barbui, T. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200206 · Cited by 61
Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies
Kuratsune, H., Suehisa, E., Kitani, T., Iwatani, Y., Kanakura, Y., & Nojima, J. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-10-0608 · Cited by 58
Evidence-based indications for thrombophilia screening
Lindhoff-Last, & Luxembourg (2008) · VASA · doi:10.1024/0301-1526.37.1.19 · Cited by 57
The Clinical Spectrum of Antiphospholipid Syndrome
Baker, W., & Bick, R. L. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.10.007 · Cited by 56
ANTIPHOSPHOLIPID ANTIBODIES AND THE ENDOTHELIUM
Meroni, P. L., Raschi, E., Testoni, C., Tincani, A., & Balestrieri, G. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70222-2 · Cited by 56
The diagnosis and treatment of venous thromboembolism
Wells, P., & Anderson, D. (2013) · Hematology · doi:10.1182/asheducation-2013.1.457 · Cited by 70
Anti‐prothrombin antibodies combined with lupus anti‐coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus
Nojima, J., Kuratsune, H., Suehisa, E., Futsukaichi, Y., Yamanishi, H., Machii, T., Kitani, T., Iwatani, Y., & Kanakura, Y. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02950.x · Cited by 54
Endothelium as a target for antiphospholipid antibodies
Riboldi, P., Gerosa, M., Raschi, E., Testoni, C., & Meroni, P. L. (2003) · Immunobiology · doi:10.1078/0171-2985-00211 · Cited by 54
Antiphospholipid syndrome: An evolving story
Robertson, B. J., & Greaves, M. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.12.001 · Cited by 54
Thrombosis and the Antiphospholipid Syndrome
Ortel, T. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.462 · Cited by 53
Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays
Vikerfors, A., Johansson, A.-B., Gustafsson, J. T., Jonsen, A., Leonard, D., Zickert, A., Nordmark, G., Sturfelt, G., Bengtsson, A., Ronnblom, L., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes252 · Cited by 51
Self-citation
MANAGEMENT OF THROMBOSIS IN ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Petri, M. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70225-8 · Cited by 51
Management of Antiphospholipid Syndrome in Pregnancy
Petri, M., & Qazi, U. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.007 · Cited by 50
Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia
Ciampa, A., Margaglione, M., Scenna, G., Iannaccone, L., Brancaccio, V., & Ames, P. R. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0723 · Cited by 49
The Antiphospholipid Syndrome
Rand, J. H. (2007) · Hematology · doi:10.1182/asheducation-2007.1.136 · Cited by 49
Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure
Lee, A., & Crowther, M. A. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0555-z · Cited by 48
Management of thrombophilia
Bauer, K. A. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00274.x · Cited by 48
Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Bertolaccini, M. L., & Khamashta, M. A. (2006) · Lupus · doi:10.1191/0961203306lu2293rr · Cited by 47
Management of Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Pregnancy
Ruiz‐Irastorza, G., & Khamashta, M. A. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.105 · Cited by 46
Linkage mapping of a novel susceptibility locus for Beh�et's disease to chromosome 6p22-23
G�l, A., Hajeer, A. H., Worthington, J., Ollier, W., & Silman, A. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200111)44:11 · Cited by 63
Peri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 46
An approach to the patient with retiform purpura
Wysong, A. S., & Venkatesan, P. (2011) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2011.01392.x · Cited by 45
Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children
Gökçe, M., Bilginer, Y., Beşbaş, N., Özaltın, F., Cetin, M., Gümrük, F., & Özen, S. (2012) · Lupus · doi:10.1177/0961203312443721 · Cited by 45
Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta‐analysis
Ortel, T. L., Meleth, S., Catellier, D., Crowther, M. A., Erkan, D., Fortin, P. R., Garcia, D. A., Haywood, N., Kosinski, A. S., Levine, S. R., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14936 · Cited by 46
Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?
Carroll, B., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18755927 · Cited by 44
Long‐duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy
Dentali, F., Manfredi, E., Crowther, M. A., & Ageno, W. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01516.x · Cited by 44
Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
Palareti, G. (2012) · Scientifica · doi:10.6064/2012/391734 · Cited by 44
Acquired activated protein C resistance is associated with the co‐existence of anti‐prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus
Nojima, J., Kuratsune, H., Suehisa, E., Kawasaki, T., Machii, T., Kitani, T., Iwatani, Y., & Kanakura, Y. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03642.x · Cited by 44
Antiphospholipid (Hughes) Syndrome
Khamashta, M. A., Bertolaccini, M. L., & Hughes, G. R. V. (2004) · Autoimmunity · doi:10.1080/08916930410001708706 · Cited by 44
Long-Term Prospective Study of Recurrent Venous Thromboembolism in Patients Younger than 50 Years
García-Fuster, M. J., Forner, M.-J., Fernández, C., Gil, J., Vayá, A., & Maldonado, L. (2005) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000088541 · Cited by 43
Epidemiology of the Antiphospholipid Syndrome
Durcan, L., & Petri, M. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00002-8 · Cited by 43
The role of dyslipidemia and statins in venous thromboembolism
Ray, J. G., & Rosendaal, F. R. (2001) · Trials · doi:10.1186/cvm-2-4-165 · Cited by 42
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome
Khamashta, M. A. (1998) · Lupus · doi:10.1177/096120339800700235 · Cited by 42
The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg
Lindmarker, P., Schulman, S., & THE DURAC TRIAL STUDY GROUP (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00662.x · Cited by 41
Self-citation
Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis
Meroni, P. L., Moia, M., Derksen, R. H. W. M., Tincani, A., McIntyre, J. A., Arnout, J., Koike, T., Pietté, J. C., Khamashta, M. A., & Shoenfeld, Y. (2003) · Lupus · doi:10.1191/0961203303lu389oa · Cited by 41
Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome
Ruiz‐Irastorza, G., Khamashta, M. A., & Hughes, G. R. (2001) · Lupus · doi:10.1191/096120301667789546 · Cited by 41
Antiphospholipid antibodies and thrombosis
Greaves, M. (1999) · The Lancet · doi:10.1016/s0140-6736(05)76636-8 · Cited by 41
Diagnosis of antiphospholipid syndrome
Bertolaccini, M. L., Khamashta, M. A., & Hughes, G. R. V. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0017 · Cited by 40
The antiphospholipid syndrome – often overlooked cause of vascular occlusions?
Svenungsson, E., & Antovič, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13022 · Cited by 39
Self-citation
Cessation of oral anticoagulants in antiphospholipid syndrome
Comarmond, C., Jégo, P., Veyssier-Belot, C., Marié, I., MEKINIAN, A., Elmaleh-Sachs, A., Leroux, G., Saadoun, D., Oziol, E., Fraisse, T., et al. (2017) · Lupus · doi:10.1177/0961203317699285 · Cited by 39
ANTIPHOSPHOLIPID (HUGHES) SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS
Amigo, M., & Khamashta, M. A. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70141-1 · Cited by 39
Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis
Auerbach, A. D., Sanders, G. D., & Hambleton, J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.01.017 · Cited by 39
Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis.
Brunner, H. I., Chan, W., Ginsberg, J. S., & Feldman, B. M. (2002) · PubMed · Cited by 39
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
Les, Í., Ruiz‐Irastorza, G., & Khamashta, M. A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304720 · Cited by 38
Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus
Alessandri, C., Bombardieri, M., Prospero, L. D., Conigliaro, P., Conti, F., Labbadia, G., Misasi, R., Sorice, M., & Valesini, G. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02727.x · Cited by 38
Anti-β2-Glycoprotein I Antibodies in Patients with Acute Venous Thromboembolism
Zanon, E., Prandoni, P., Vianello, F., Saggiorato, G., Carraro, G., Bagatella, P., & Girolami, A. (1999) · Thrombosis Research · doi:10.1016/s0049-3848(99)00105-x · Cited by 38
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 37
HIV Infection and Antiphospholipid Antibody: Literature Review and Link to the Antiphospholipid Syndrome
Hassoun, A., Al-Kadhimi, Z. S., & Cervia, J. S. (2004) · AIDS Patient Care and STDs · doi:10.1089/1087291041444032 · Cited by 37
Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism
Kearon, C. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328356745b · Cited by 37
Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease
Puisieux, F. L., de Groote, P., Masy, E., Pompéo, C. D., Millaire, A., Bouillanne, O., Jude, B., Dewailly, P., & Ducloux, G. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00600-8 · Cited by 36
Renal manifestations of the antiphospholipid syndrome
D’Cruz, D. P. (2005) · Lupus · doi:10.1191/0961203305lu2058oa · Cited by 36
Autoantibodies in connective tissue disease
Mulhearn, B., Tansley, S., & McHugh, N. J. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101462 · Cited by 35
Evidence based treatment of the antiphospholipid syndrome
Crowther, M. A., & Wislöff, F. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.041 · Cited by 34
Thrombosis in systemic lupus erythematosus: risk and protection
Burgos, P. I., & Alarcón, G. S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.137 · Cited by 34
Recent insights into antiphospholipid antibody-mediated thrombosis
Field, S. L., Brighton, T., McNeil, H. P., & Chesterman, C. N. (1999) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.1999.0033 · Cited by 34
LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES
Thiagarajan, P., & Shapiro, S. S. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70048-4 · Cited by 34
Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis
Pastori, D., Bucci, T., Triggiani, M., Ames, P. R. J., Parrotto, S., Violi, F., Pignatelli, P., & Farcomeni, A. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.005 · Cited by 33
Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome
Ioannou, Y., & Rahman, A. (2010) · Lupus · doi:10.1177/0961203309360544 · Cited by 33
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Garcia, D. A., Khamashta, M. A., & Crowther, M. A. (2007) · Blood · doi:10.1182/blood-2006-10-041814 · Cited by 33
Antiphospholipid antibiodies: a critical review of the literature
Lim, W., & Crowther, M. A. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282a4a65f · Cited by 32
Testing for and Clinical Significance of Anticardiolipin Antibodies
Reddel, S., & Krilis, S. A. (1999) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.6.6.775-782.1999 · Cited by 32
Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview
Atanassova, P. A. (2007) · Yonsei Medical Journal · doi:10.3349/ymj.2007.48.6.901 · Cited by 31
Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Valle, P. D., Crippa, L., Garlando, A. M., Pattarini, E., Safa, O., D’Angelo, S., & D’Angelo, A. (1999) · PubMed · Cited by 31
Thrombophilia: Clinical and Laboratory Assessment and Management
Heit, J. A. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10014-8 · Cited by 31
The Antiphospholipid Syndrome
D’Cruz, D. P., & Khamashta, M. A. (2009) · Springer eBooks · doi:10.1007/978-1-84800-934-9_16 · Cited by 31
Towards evidence-based treatment of thrombotic antiphospholipid syndrome
Derksen, R. H. W. M., & de Groot, P. G. (2010) · Lupus · doi:10.1177/0961203309361483 · Cited by 30
Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model
Vink, R., Kraaijenhagen, R. A., Levi, M. M., & Buller, H. R. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00466.x · Cited by 30
Stroke and antiphospholipid syndrome: the treatment debate
Ruiz‐Irastorza, G., & Khamashta, M. A. (2005) · Rheumatology · doi:10.1093/rheumatology/keh666 · Cited by 30
Predicting the risk of recurrent venous thromboembolism (VTE)
Streiff, M. B. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1188-4 · Cited by 30
Hughes syndrome crosses boundaries
Ruiz‐Irastorza, G., Khamashta, M. A., & Hughes, G. R. V. (2002) · Autoimmunity Reviews · doi:10.1016/s1568-9972(01)00005-2 · Cited by 28
The antiphospholipid syndrome
Pasquali, J., Poindron, V., Korganow, A., & Martin, T. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.08.008 · Cited by 28
Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term
de Jong, P. G., Coppens, M., & Middeldorp, S. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09196.x · Cited by 27
New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism
Ögren, M., & Schulman, S. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-05-0235 · Cited by 27
Self-citation
Low-Intensity versus Conventional-Intensity Warfarin for Prevention of Recurrent Venous Thromboembolism
Huisman, M. V., van der Meer, F. J. M., van Rooden, C. J., & Prins, M. H. (2003) · New England Journal of Medicine · doi:10.1056/nejm200311273492216 · Cited by 27
The Effects of Low-intensity Warfarin on Coagulation Activation in Patients with Antiphospholipid Antibodies and Systemic Lupus Erythematosus
Crowther, M., Julian, J., Stewart, K., Donovan, D., Kaminska, E., Laskin, C., Ginsberg, J., & Douketis, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614324 · Cited by 27
Anticardiolipin and anti-beta-2-glycoprotein I antibodies
Marai, I., Tincani, A., Balestrieri, G., & Shoenfeld, Y. (2005) · Autoimmunity · doi:10.1080/08916930400022608 · Cited by 27
Unresolved issues in anticoagulant therapy
Schulman, S. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00269.x · Cited by 27
Self-citation
Erratum
Palareti, G., & Cosmi, B. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000132310.18883.c0 · Cited by 27
Anticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Blood · doi:10.1182/blood-2018-05-848697 · Cited by 26
The management of patients who require temporary reversal of vitamin K antagonists for surgery: a practical guide for clinicians
Mannucci, C., & Douketis, J. D. (2006) · Internal and Emergency Medicine · doi:10.1007/bf02936533 · Cited by 26
Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 26
Antiphospholipid Syndrome: Review
Sammaritano, L. R. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166748.90089.65 · Cited by 26
Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis?
Bertolaccini, M. L., & Hughes, G. R. V. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.001 · Cited by 26
The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects
Cuadrado, M. J., & Khamashta, M. A. (2000) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.1999.0083 · Cited by 25
Which Antiphospholipid Antibodies Should Be Measured in the Antiphospholipid Syndrome?
Galli, M. (2000) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000054164 · Cited by 25
High prevalence of anti‐prothrombin antibody in patients with deep vein thrombosis
Ishikura, K., Wada, H., Kamikura, Y., Hattori, K., Fukuzawa, T., Yamada, N., Nakamura, M., Nobori, T., & Nakano, T. (2004) · American Journal of Hematology · doi:10.1002/ajh.20124 · Cited by 25
Venous thrombosis: understanding the paradoxes of recurrence
Cannegieter, S. C., & Vlieg, A. V. H. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12263 · Cited by 25
Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis.
Cerdà, P., Becattini, C., Iriarte, A., Cortés-Hernández, J., Corbella, X., & Riera‐Mestre, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.012 · Cited by 25
The treatment of antiphospholipid syndrome: A harmonic contrast
Ruiz‐Irastorza, G., & Khamashta, M. A. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.10.003 · Cited by 23
Recurrent Thrombosis in Patients with Deep Vein Thrombosis and/or Venous Thromboembolism Associated with Anticardiolipin Antibodies
de Godoy, J. M. P., de Godoy, M. F., & Braile, D. M. (2006) · Angiology · doi:10.1177/000331970605700111 · Cited by 23
How to prevent, treat, and overcome current clinical challenges of VTE
van Es, J., Eerenberg, E. S., Kamphuisen, P. W., & Buller, H. R. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04334.x · Cited by 22
Loss of antiphospholipid antibody positivity post-thrombosis in SLE
Khawaja, M., Magder, L. S., GOLDMAN, D. W., & Petri, M. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000423 · Cited by 22
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Fonseca, A. G., & D’Cruz, D. P. (2008) · Journal of Autoimmune Diseases · doi:10.1186/1740-2557-5-6 · Cited by 23
Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis
Aibar, J., & Schulman, S. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1725057 · Cited by 22
Self-citation
The wound/burn guidelines – 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis
Fujimoto, M., Asano, Y., Ishii, T., Ogawa, F., Kawakami, T., Kodera, M., Abe, M., Isei, T., Ito, T., Inoue, Y., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13275 · Cited by 21
Antiphospholipid Syndrome and Thrombosis
Branch, D. W., & Eller, A. (2006) · Clinical Obstetrics & Gynecology · doi:10.1097/01.grf.0000211955.61121.3b · Cited by 21
Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis
Caprio, F., & Bernstein, R. A. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9661-1 · Cited by 21

Authors: Schulman, S., Svenungsson, E., & Granqvist, S.
Affiliations: Karolinska University Hospital (SE)
Ersta sjukhus (SE)
Corresponding author: Schulman, Sam
ORCID: Schulman, Sam
Svenungsson, Elisabet
Venue: The American Journal of Medicine
Publisher: Elsevier BV
Published: 1998-04
Volume: 104
Issue: 4
Pages: 332-338
ISSN: 0002-9343 (ISSN-L)
DOI: 10.1016/s0002-9343(98)00060-6
OpenAlex: W2152900444
Cited by: 497
References: 24
Citations by year: 2026: 3 · 2025: 3 · 2024: 9 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 13 · 2018: 9 · 2017: 10 · 2016: 13 · 2015: 8 · 2014: 9 · 2013: 18 · 2012: 21
FWCI: 19.61
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The American Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Hjärt-Lungfonden
Karolinska Institutet
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords: anticardiolipin antibodies, antiphospholipid antibodies, venous thromboembolism, thromboembolism recurrence, oral anticoagulation, long-term anticoagulation, mortality, antibody titers, international normalized ratio
MeSH terms: Aged, Anticoagulants, Cause of Death, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Recurrence, Risk, Thromboembolism, Antibodies, Anticardiolipin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks